| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cognitive Dysfunction | 27 | 2026 | 271 | 6.800 |
Why?
|
| Neurovascular Coupling | 18 | 2024 | 154 | 6.140 |
Why?
|
| Aging | 43 | 2026 | 1017 | 5.680 |
Why?
|
| Cerebrovascular Circulation | 17 | 2024 | 224 | 3.590 |
Why?
|
| Cognition | 9 | 2025 | 331 | 2.930 |
Why?
|
| Matrix Metalloproteinase 9 | 16 | 2021 | 54 | 2.660 |
Why?
|
| Myocardial Infarction | 15 | 2026 | 351 | 2.540 |
Why?
|
| Ventricular Remodeling | 17 | 2026 | 32 | 2.220 |
Why?
|
| Endothelium, Vascular | 15 | 2026 | 334 | 2.210 |
Why?
|
| Brain | 17 | 2025 | 770 | 1.900 |
Why?
|
| Spectroscopy, Near-Infrared | 4 | 2024 | 75 | 1.660 |
Why?
|
| Peripheral Arterial Disease | 3 | 2025 | 144 | 1.530 |
Why?
|
| Dementia, Vascular | 6 | 2026 | 57 | 1.460 |
Why?
|
| Cerebral Hemorrhage | 7 | 2023 | 93 | 1.410 |
Why?
|
| Oxidative Stress | 13 | 2026 | 677 | 1.400 |
Why?
|
| Mice, Inbred C57BL | 37 | 2025 | 1658 | 1.370 |
Why?
|
| Myocardium | 7 | 2026 | 196 | 1.370 |
Why?
|
| Animals | 70 | 2026 | 10699 | 1.340 |
Why?
|
| Alzheimer Disease | 6 | 2023 | 225 | 1.290 |
Why?
|
| Male | 48 | 2025 | 13934 | 1.240 |
Why?
|
| Hypertension | 6 | 2023 | 309 | 1.240 |
Why?
|
| Humans | 62 | 2026 | 28884 | 1.200 |
Why?
|
| Aged | 22 | 2025 | 5599 | 1.170 |
Why?
|
| NAD | 4 | 2025 | 104 | 1.080 |
Why?
|
| Dietary Supplements | 4 | 2025 | 273 | 1.030 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2023 | 841 | 1.020 |
Why?
|
| Mice | 40 | 2025 | 4808 | 0.980 |
Why?
|
| Vasodilation | 4 | 2024 | 115 | 0.960 |
Why?
|
| Cerebrovascular Disorders | 3 | 2020 | 46 | 0.930 |
Why?
|
| White Matter | 2 | 2023 | 90 | 0.920 |
Why?
|
| Niacinamide | 1 | 2025 | 32 | 0.900 |
Why?
|
| Sleep Deprivation | 2 | 2021 | 28 | 0.890 |
Why?
|
| Mitochondria | 8 | 2026 | 408 | 0.830 |
Why?
|
| Hemodynamics | 2 | 2021 | 221 | 0.830 |
Why?
|
| Inflammation | 12 | 2026 | 668 | 0.820 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2023 | 14 | 0.800 |
Why?
|
| Astrocytes | 3 | 2021 | 80 | 0.790 |
Why?
|
| Microcirculation | 8 | 2021 | 113 | 0.760 |
Why?
|
| Rejuvenation | 5 | 2026 | 33 | 0.760 |
Why?
|
| Cellular Senescence | 8 | 2025 | 141 | 0.750 |
Why?
|
| Female | 26 | 2025 | 15634 | 0.720 |
Why?
|
| Dementia | 1 | 2023 | 97 | 0.720 |
Why?
|
| Motor Cortex | 1 | 2021 | 48 | 0.680 |
Why?
|
| Collagen | 5 | 2017 | 156 | 0.680 |
Why?
|
| Heart Failure | 3 | 2023 | 253 | 0.670 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2020 | 23 | 0.670 |
Why?
|
| Heart Ventricles | 5 | 2023 | 139 | 0.660 |
Why?
|
| Fasting | 3 | 2026 | 91 | 0.650 |
Why?
|
| Middle Aged | 10 | 2025 | 7416 | 0.640 |
Why?
|
| Heart | 3 | 2025 | 232 | 0.630 |
Why?
|
| Disease Models, Animal | 20 | 2023 | 1508 | 0.630 |
Why?
|
| Hypogonadism | 1 | 2019 | 6 | 0.630 |
Why?
|
| Hormone Replacement Therapy | 1 | 2019 | 9 | 0.630 |
Why?
|
| Androgens | 1 | 2019 | 47 | 0.620 |
Why?
|
| Retinal Artery | 1 | 2019 | 10 | 0.610 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 49 | 0.610 |
Why?
|
| Nicotinamide Mononucleotide | 4 | 2020 | 23 | 0.610 |
Why?
|
| Testosterone | 1 | 2019 | 74 | 0.610 |
Why?
|
| Geriatrics | 2 | 2019 | 47 | 0.610 |
Why?
|
| Macrophages | 8 | 2017 | 305 | 0.600 |
Why?
|
| Extracellular Matrix | 4 | 2017 | 117 | 0.600 |
Why?
|
| Blood-Brain Barrier | 6 | 2026 | 97 | 0.600 |
Why?
|
| Photic Stimulation | 1 | 2019 | 71 | 0.600 |
Why?
|
| Visual Perception | 1 | 2019 | 45 | 0.600 |
Why?
|
| Neovascularization, Physiologic | 4 | 2019 | 124 | 0.600 |
Why?
|
| Cognition Disorders | 1 | 2020 | 186 | 0.590 |
Why?
|
| Vascular Stiffness | 1 | 2019 | 41 | 0.590 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2019 | 64 | 0.580 |
Why?
|
| Insulin-Like Growth Factor I | 5 | 2019 | 301 | 0.580 |
Why?
|
| Fibroblasts | 3 | 2017 | 160 | 0.580 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 1 | 2017 | 16 | 0.530 |
Why?
|
| Endothelial Cells | 6 | 2026 | 373 | 0.530 |
Why?
|
| Lameness, Animal | 1 | 2017 | 8 | 0.520 |
Why?
|
| Hypertension, Pulmonary | 1 | 2017 | 34 | 0.520 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 2 | 2015 | 14 | 0.510 |
Why?
|
| Radiation Injuries, Experimental | 1 | 2017 | 31 | 0.510 |
Why?
|
| Aged, 80 and over | 5 | 2025 | 2065 | 0.500 |
Why?
|
| Syndecan-4 | 1 | 2015 | 4 | 0.460 |
Why?
|
| NF-E2-Related Factor 2 | 4 | 2024 | 122 | 0.460 |
Why?
|
| Prospective Studies | 3 | 2023 | 1280 | 0.420 |
Why?
|
| Wound Healing | 4 | 2026 | 126 | 0.410 |
Why?
|
| Cardiovascular System | 1 | 2013 | 41 | 0.400 |
Why?
|
| Adult | 7 | 2023 | 8030 | 0.390 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2013 | 13 | 0.390 |
Why?
|
| Biomarkers | 7 | 2024 | 777 | 0.390 |
Why?
|
| Age Factors | 9 | 2021 | 737 | 0.380 |
Why?
|
| Cardiovascular Diseases | 2 | 2013 | 381 | 0.380 |
Why?
|
| Hippocampus | 4 | 2023 | 198 | 0.380 |
Why?
|
| Transcriptome | 3 | 2025 | 231 | 0.370 |
Why?
|
| Signal Transduction | 9 | 2026 | 1469 | 0.370 |
Why?
|
| Risk Assessment | 4 | 2020 | 631 | 0.370 |
Why?
|
| Reference Values | 3 | 2019 | 200 | 0.360 |
Why?
|
| Neuropsychological Tests | 3 | 2023 | 249 | 0.360 |
Why?
|
| Microvessels | 3 | 2021 | 86 | 0.360 |
Why?
|
| Neuroprotective Agents | 1 | 2012 | 52 | 0.360 |
Why?
|
| Organometallic Compounds | 1 | 2012 | 42 | 0.360 |
Why?
|
| Brain Injuries | 1 | 2012 | 50 | 0.350 |
Why?
|
| Leukocytes | 2 | 2015 | 72 | 0.350 |
Why?
|
| Aorta | 2 | 2024 | 124 | 0.350 |
Why?
|
| Parabiosis | 2 | 2022 | 17 | 0.340 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2025 | 344 | 0.340 |
Why?
|
| Arterioles | 2 | 2022 | 61 | 0.330 |
Why?
|
| Obesity | 4 | 2024 | 701 | 0.330 |
Why?
|
| Cerebral Cortex | 2 | 2021 | 136 | 0.320 |
Why?
|
| Hyperemia | 2 | 2021 | 40 | 0.320 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 995 | 0.320 |
Why?
|
| Exercise | 2 | 2025 | 498 | 0.320 |
Why?
|
| Young Adult | 3 | 2022 | 2839 | 0.300 |
Why?
|
| Liposomes | 2 | 2021 | 145 | 0.300 |
Why?
|
| Memory, Short-Term | 4 | 2022 | 64 | 0.300 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2020 | 64 | 0.300 |
Why?
|
| Brain Mapping | 2 | 2021 | 207 | 0.290 |
Why?
|
| Mice, Knockout | 7 | 2018 | 874 | 0.290 |
Why?
|
| Vascular Diseases | 2 | 2019 | 68 | 0.290 |
Why?
|
| Random Allocation | 4 | 2019 | 151 | 0.280 |
Why?
|
| Carotid Artery Diseases | 2 | 2021 | 37 | 0.270 |
Why?
|
| Inflammation Mediators | 4 | 2026 | 169 | 0.270 |
Why?
|
| Models, Animal | 2 | 2020 | 130 | 0.260 |
Why?
|
| Stroke | 1 | 2010 | 261 | 0.260 |
Why?
|
| Ventricular Function, Left | 5 | 2020 | 115 | 0.260 |
Why?
|
| Cohort Studies | 2 | 2019 | 897 | 0.250 |
Why?
|
| Pilot Projects | 2 | 2025 | 464 | 0.250 |
Why?
|
| Myocytes, Cardiac | 3 | 2016 | 64 | 0.250 |
Why?
|
| Neoplasms | 2 | 2025 | 874 | 0.240 |
Why?
|
| Phenotype | 6 | 2021 | 686 | 0.240 |
Why?
|
| Lipoproteins, LDL | 1 | 2026 | 42 | 0.240 |
Why?
|
| Disease Progression | 3 | 2023 | 477 | 0.230 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2025 | 10 | 0.230 |
Why?
|
| Pyridinium Compounds | 1 | 2025 | 27 | 0.230 |
Why?
|
| Retina | 3 | 2024 | 445 | 0.230 |
Why?
|
| Smartphone | 1 | 2025 | 75 | 0.220 |
Why?
|
| Reactive Oxygen Species | 2 | 2024 | 292 | 0.220 |
Why?
|
| Administration, Oral | 1 | 2025 | 190 | 0.220 |
Why?
|
| Middle Cerebral Artery | 2 | 2023 | 54 | 0.220 |
Why?
|
| Pandemics | 2 | 2023 | 202 | 0.220 |
Why?
|
| Cancer Survivors | 1 | 2025 | 72 | 0.220 |
Why?
|
| Longitudinal Studies | 2 | 2023 | 429 | 0.210 |
Why?
|
| Resilience, Psychological | 1 | 2024 | 18 | 0.210 |
Why?
|
| Hyperhomocysteinemia | 1 | 2023 | 29 | 0.210 |
Why?
|
| Electroretinography | 1 | 2024 | 180 | 0.200 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2023 | 36 | 0.200 |
Why?
|
| Maze Learning | 3 | 2019 | 78 | 0.200 |
Why?
|
| Observational Studies as Topic | 1 | 2023 | 55 | 0.200 |
Why?
|
| Pulse Wave Analysis | 2 | 2022 | 30 | 0.200 |
Why?
|
| Mice, Transgenic | 6 | 2021 | 513 | 0.190 |
Why?
|
| Treatment Outcome | 3 | 2025 | 2426 | 0.190 |
Why?
|
| Cell Movement | 3 | 2019 | 376 | 0.190 |
Why?
|
| Retinal Vessels | 2 | 2021 | 75 | 0.190 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2019 | 554 | 0.190 |
Why?
|
| Cognitive Aging | 2 | 2020 | 22 | 0.190 |
Why?
|
| Gene Expression Profiling | 4 | 2025 | 465 | 0.190 |
Why?
|
| Immunohistochemistry | 2 | 2015 | 465 | 0.190 |
Why?
|
| Deoxyguanosine | 1 | 2022 | 14 | 0.190 |
Why?
|
| Fibrosis | 4 | 2017 | 143 | 0.190 |
Why?
|
| Neutrophils | 2 | 2016 | 185 | 0.190 |
Why?
|
| Longevity | 3 | 2019 | 141 | 0.190 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2021 | 11 | 0.180 |
Why?
|
| Neuronal Plasticity | 2 | 2019 | 51 | 0.180 |
Why?
|
| Metabolic Syndrome | 1 | 2022 | 80 | 0.180 |
Why?
|
| Aniline Compounds | 1 | 2021 | 23 | 0.180 |
Why?
|
| Reaction Time | 1 | 2021 | 95 | 0.170 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2021 | 41 | 0.170 |
Why?
|
| Microscopy, Fluorescence, Multiphoton | 1 | 2021 | 8 | 0.170 |
Why?
|
| Cations | 1 | 2021 | 11 | 0.170 |
Why?
|
| Intravital Microscopy | 1 | 2021 | 10 | 0.170 |
Why?
|
| Microvascular Rarefaction | 1 | 2021 | 13 | 0.170 |
Why?
|
| Iodine Radioisotopes | 1 | 2021 | 36 | 0.170 |
Why?
|
| Sex Factors | 2 | 2020 | 467 | 0.170 |
Why?
|
| Sulfonamides | 1 | 2021 | 73 | 0.170 |
Why?
|
| Neurosciences | 1 | 2020 | 10 | 0.170 |
Why?
|
| Prefrontal Cortex | 1 | 2021 | 80 | 0.170 |
Why?
|
| High-Intensity Interval Training | 1 | 2020 | 9 | 0.170 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2020 | 6 | 0.170 |
Why?
|
| Renin-Angiotensin System | 1 | 2020 | 18 | 0.160 |
Why?
|
| Capillary Permeability | 1 | 2021 | 56 | 0.160 |
Why?
|
| Quality of Life | 2 | 2025 | 521 | 0.160 |
Why?
|
| Diastole | 3 | 2017 | 22 | 0.160 |
Why?
|
| Tomography, Optical Coherence | 1 | 2021 | 96 | 0.160 |
Why?
|
| Wet Macular Degeneration | 1 | 2019 | 9 | 0.160 |
Why?
|
| Sequence Analysis, RNA | 1 | 2020 | 58 | 0.160 |
Why?
|
| Rats | 3 | 2014 | 1588 | 0.160 |
Why?
|
| Sirtuin 1 | 1 | 2020 | 41 | 0.160 |
Why?
|
| Phenanthrenes | 1 | 2019 | 10 | 0.160 |
Why?
|
| Choroid | 1 | 2019 | 21 | 0.160 |
Why?
|
| Drug Carriers | 1 | 2021 | 119 | 0.160 |
Why?
|
| Radiation Injuries | 1 | 2020 | 52 | 0.160 |
Why?
|
| Antioxidants | 2 | 2019 | 224 | 0.150 |
Why?
|
| Catalase | 1 | 2019 | 49 | 0.150 |
Why?
|
| Case-Control Studies | 1 | 2021 | 739 | 0.150 |
Why?
|
| Exercise Test | 1 | 2020 | 249 | 0.150 |
Why?
|
| Cytokines | 3 | 2019 | 451 | 0.150 |
Why?
|
| Psychomotor Disorders | 1 | 2019 | 5 | 0.150 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2019 | 37 | 0.150 |
Why?
|
| Oxygen | 1 | 2020 | 237 | 0.150 |
Why?
|
| Gait | 4 | 2021 | 61 | 0.150 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 1 | 2019 | 15 | 0.150 |
Why?
|
| Ligation | 2 | 2018 | 39 | 0.150 |
Why?
|
| Neurons | 1 | 2021 | 297 | 0.150 |
Why?
|
| Macrophages, Peritoneal | 1 | 2019 | 10 | 0.150 |
Why?
|
| Platelet Factor 4 | 1 | 2019 | 5 | 0.150 |
Why?
|
| Gene Expression Regulation | 2 | 2020 | 634 | 0.150 |
Why?
|
| CD36 Antigens | 1 | 2019 | 8 | 0.150 |
Why?
|
| Cerebral Veins | 1 | 2019 | 11 | 0.150 |
Why?
|
| Eicosanoids | 1 | 2019 | 10 | 0.150 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2019 | 38 | 0.150 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2019 | 48 | 0.150 |
Why?
|
| Cerebral Arteries | 1 | 2019 | 33 | 0.150 |
Why?
|
| Regional Blood Flow | 1 | 2019 | 164 | 0.150 |
Why?
|
| Valsalva Maneuver | 1 | 2018 | 8 | 0.150 |
Why?
|
| Phagocytosis | 1 | 2019 | 80 | 0.140 |
Why?
|
| Echocardiography | 2 | 2016 | 110 | 0.140 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2018 | 43 | 0.140 |
Why?
|
| DNA Damage | 1 | 2019 | 152 | 0.140 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 485 | 0.140 |
Why?
|
| Connective Tissue Growth Factor | 1 | 2017 | 9 | 0.140 |
Why?
|
| Sepsis | 1 | 2018 | 86 | 0.130 |
Why?
|
| Genetic Pleiotropy | 1 | 2017 | 9 | 0.130 |
Why?
|
| Gene Expression | 2 | 2018 | 417 | 0.130 |
Why?
|
| Cardiomegaly | 1 | 2016 | 18 | 0.130 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2017 | 59 | 0.130 |
Why?
|
| Software | 1 | 2018 | 127 | 0.130 |
Why?
|
| Databases, Factual | 1 | 2018 | 270 | 0.130 |
Why?
|
| Nanoparticles | 1 | 2021 | 291 | 0.130 |
Why?
|
| Time Factors | 2 | 2021 | 1613 | 0.130 |
Why?
|
| Interleukin-10 | 1 | 2017 | 74 | 0.130 |
Why?
|
| Neovascularization, Pathologic | 1 | 2017 | 148 | 0.130 |
Why?
|
| Hypoxia | 1 | 2017 | 90 | 0.120 |
Why?
|
| Blood Vessels | 1 | 2016 | 58 | 0.120 |
Why?
|
| Sex Characteristics | 1 | 2017 | 173 | 0.120 |
Why?
|
| Health Status | 1 | 2017 | 149 | 0.120 |
Why?
|
| Tibial Fractures | 1 | 2016 | 16 | 0.120 |
Why?
|
| Tibia | 1 | 2016 | 39 | 0.120 |
Why?
|
| Collagen Type I | 1 | 2015 | 27 | 0.120 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2015 | 11 | 0.120 |
Why?
|
| MicroRNAs | 1 | 2019 | 302 | 0.120 |
Why?
|
| Peptides | 1 | 2018 | 296 | 0.120 |
Why?
|
| Behavior, Animal | 2 | 2019 | 108 | 0.120 |
Why?
|
| Microglia | 2 | 2019 | 69 | 0.120 |
Why?
|
| Bone Density | 1 | 2016 | 101 | 0.110 |
Why?
|
| Angiotensin II | 3 | 2021 | 55 | 0.110 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2015 | 133 | 0.110 |
Why?
|
| Deuterium Oxide | 1 | 2014 | 3 | 0.110 |
Why?
|
| Isotope Labeling | 1 | 2014 | 31 | 0.110 |
Why?
|
| Survival Analysis | 1 | 2015 | 288 | 0.110 |
Why?
|
| Citrate (si)-Synthase | 1 | 2014 | 23 | 0.110 |
Why?
|
| Blood Proteins | 1 | 2014 | 68 | 0.110 |
Why?
|
| Hypertrophy | 1 | 2014 | 46 | 0.110 |
Why?
|
| Thrombospondin 1 | 1 | 2013 | 8 | 0.100 |
Why?
|
| Angiopoietin-2 | 1 | 2013 | 10 | 0.100 |
Why?
|
| Chemokine CCL2 | 1 | 2013 | 47 | 0.100 |
Why?
|
| Substrate Specificity | 1 | 2013 | 151 | 0.100 |
Why?
|
| Structure-Activity Relationship | 1 | 2013 | 209 | 0.100 |
Why?
|
| Laminin | 1 | 2013 | 21 | 0.100 |
Why?
|
| Neutrophil Infiltration | 1 | 2013 | 19 | 0.100 |
Why?
|
| Fibronectins | 1 | 2013 | 28 | 0.100 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2013 | 94 | 0.100 |
Why?
|
| Proteoglycans | 1 | 2013 | 38 | 0.100 |
Why?
|
| Protein Conformation | 1 | 2013 | 259 | 0.100 |
Why?
|
| Myofibroblasts | 1 | 2013 | 23 | 0.100 |
Why?
|
| Up-Regulation | 1 | 2013 | 247 | 0.100 |
Why?
|
| Systole | 1 | 2012 | 24 | 0.100 |
Why?
|
| Proteome | 1 | 2013 | 79 | 0.090 |
Why?
|
| Ankle Brachial Index | 2 | 2022 | 34 | 0.090 |
Why?
|
| Atherosclerosis | 3 | 2019 | 97 | 0.090 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 215 | 0.090 |
Why?
|
| Survival Rate | 1 | 2012 | 432 | 0.080 |
Why?
|
| Neurologic Examination | 1 | 2010 | 22 | 0.080 |
Why?
|
| Leukocyte Count | 1 | 2010 | 25 | 0.080 |
Why?
|
| Blood Pressure | 2 | 2023 | 357 | 0.080 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 251 | 0.080 |
Why?
|
| Diet, High-Fat | 2 | 2024 | 144 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 465 | 0.080 |
Why?
|
| Recovery of Function | 1 | 2010 | 123 | 0.080 |
Why?
|
| NG-Nitroarginine Methyl Ester | 2 | 2019 | 31 | 0.070 |
Why?
|
| Nitric Oxide | 2 | 2019 | 153 | 0.070 |
Why?
|
| Chemokines | 2 | 2019 | 74 | 0.070 |
Why?
|
| Cell Polarity | 2 | 2017 | 22 | 0.060 |
Why?
|
| Oxidation-Reduction | 1 | 2026 | 381 | 0.060 |
Why?
|
| Cell Differentiation | 2 | 2017 | 427 | 0.050 |
Why?
|
| Risk Factors | 2 | 2020 | 2127 | 0.050 |
Why?
|
| Aldehydes | 1 | 2024 | 55 | 0.050 |
Why?
|
| Methionine | 1 | 2023 | 38 | 0.050 |
Why?
|
| Caloric Restriction | 1 | 2024 | 74 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2025 | 404 | 0.050 |
Why?
|
| Blood Flow Velocity | 1 | 2023 | 66 | 0.050 |
Why?
|
| Rest | 1 | 2023 | 96 | 0.050 |
Why?
|
| Executive Function | 1 | 2022 | 27 | 0.050 |
Why?
|
| Autonomic Nervous System | 1 | 2023 | 118 | 0.050 |
Why?
|
| Paclitaxel | 1 | 2023 | 200 | 0.050 |
Why?
|
| Muscle, Smooth | 1 | 2022 | 41 | 0.050 |
Why?
|
| Gray Matter | 1 | 2022 | 24 | 0.050 |
Why?
|
| Diet | 1 | 2023 | 241 | 0.040 |
Why?
|
| Plaque, Amyloid | 1 | 2021 | 12 | 0.040 |
Why?
|
| bcl-X Protein | 1 | 2021 | 35 | 0.040 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2021 | 34 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2021 | 68 | 0.040 |
Why?
|
| Interferons | 1 | 2021 | 70 | 0.040 |
Why?
|
| Membrane Fusion | 1 | 2021 | 7 | 0.040 |
Why?
|
| Cricetulus | 1 | 2021 | 56 | 0.040 |
Why?
|
| CHO Cells | 1 | 2021 | 96 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2020 | 32 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 138 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2021 | 114 | 0.040 |
Why?
|
| Endocytosis | 1 | 2021 | 96 | 0.040 |
Why?
|
| Calcium Signaling | 1 | 2020 | 72 | 0.040 |
Why?
|
| Endothelium | 1 | 2020 | 28 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2020 | 124 | 0.040 |
Why?
|
| Spatial Learning | 1 | 2019 | 6 | 0.040 |
Why?
|
| Lasers | 1 | 2019 | 68 | 0.040 |
Why?
|
| Sensorimotor Cortex | 1 | 2019 | 7 | 0.040 |
Why?
|
| Memory Disorders | 1 | 2019 | 50 | 0.040 |
Why?
|
| Rats, Inbred BN | 1 | 2019 | 70 | 0.040 |
Why?
|
| Rodentia | 1 | 2019 | 14 | 0.040 |
Why?
|
| Infusions, Subcutaneous | 1 | 2019 | 1 | 0.040 |
Why?
|
| ADAMTS Proteins | 1 | 2019 | 2 | 0.040 |
Why?
|
| Integrin beta4 | 1 | 2019 | 3 | 0.040 |
Why?
|
| Rats, Inbred F344 | 1 | 2019 | 174 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 128 | 0.040 |
Why?
|
| Cell Line | 1 | 2021 | 700 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2019 | 81 | 0.040 |
Why?
|
| Heart Rate | 1 | 2020 | 382 | 0.040 |
Why?
|
| Echocardiography, Doppler | 1 | 2018 | 21 | 0.040 |
Why?
|
| Motor Activity | 1 | 2019 | 148 | 0.040 |
Why?
|
| Aminoimidazole Carboxamide | 1 | 2018 | 7 | 0.040 |
Why?
|
| Ribonucleotides | 1 | 2018 | 7 | 0.040 |
Why?
|
| Hydrogen Peroxide | 1 | 2019 | 145 | 0.040 |
Why?
|
| Research | 1 | 2019 | 93 | 0.040 |
Why?
|
| Cecum | 1 | 2018 | 14 | 0.040 |
Why?
|
| Punctures | 1 | 2018 | 17 | 0.040 |
Why?
|
| Swimming | 1 | 2018 | 32 | 0.040 |
Why?
|
| Amyloidogenic Proteins | 1 | 2018 | 7 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2019 | 251 | 0.040 |
Why?
|
| Mice, Inbred ICR | 1 | 2018 | 26 | 0.040 |
Why?
|
| Prognosis | 1 | 2020 | 811 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2019 | 198 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 148 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2019 | 272 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 2017 | 28 | 0.030 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2017 | 10 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2019 | 216 | 0.030 |
Why?
|
| Matrix Metalloproteinases | 1 | 2017 | 31 | 0.030 |
Why?
|
| Cell Size | 1 | 2016 | 26 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2018 | 398 | 0.030 |
Why?
|
| Psychomotor Performance | 1 | 2017 | 72 | 0.030 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 1351 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2019 | 1022 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 2016 | 23 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 524 | 0.030 |
Why?
|
| X-Ray Microtomography | 1 | 2016 | 33 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2019 | 825 | 0.030 |
Why?
|
| Diabetic Retinopathy | 1 | 2017 | 112 | 0.030 |
Why?
|
| Cicatrix | 1 | 2015 | 14 | 0.030 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2015 | 13 | 0.030 |
Why?
|
| Cardiac Volume | 1 | 2015 | 7 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2015 | 58 | 0.030 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2015 | 40 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2016 | 108 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2015 | 65 | 0.030 |
Why?
|
| Cell Communication | 1 | 2015 | 68 | 0.030 |
Why?
|
| Safety | 1 | 2014 | 32 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2015 | 697 | 0.030 |
Why?
|
| Carotid Intima-Media Thickness | 1 | 2013 | 12 | 0.030 |
Why?
|
| United States | 1 | 2020 | 2225 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 1056 | 0.030 |
Why?
|
| Vascular Calcification | 1 | 2012 | 20 | 0.020 |
Why?
|
| Proteomics | 1 | 2014 | 197 | 0.020 |
Why?
|
| Models, Biological | 1 | 2013 | 469 | 0.020 |
Why?
|